Scholarlink

Background <p>Relapsed/refractory multiple myeloma (R/R MM) with extramedullary disease (EMD) has a poor prognosis. Responses to current therapies, including autologous hematopoietic stem cell transplantation (auto-HSCT) and chimeric antigen receptor (CAR) T-cell therapy, remain unsatisfactory or show frequent early progression despite an initial response. In this study, we aimed to investigate the efficacy of a therapeutic approach combining CAR T-therapy with auto-HSCT.</p> Methods <p>Eighteen patients with R/R MM with EMD were enrolled in clinical trials evaluating anti-BCMA CAR-T therapy. Of these, eight patients were treated in combination with auto-ASCT in combination (T-C group), while the remaining ten underwent CAR T-cell therapy alone (C group). We retrospectively compared the clinical responses, CAR T-cell expansion kinetics, T-cell subset profiles, serum interleukin-6 (IL-6) levels, treatment-related toxicities, and long-term outcomes between the two cohorts.</p> Results <p>In the T-C group, all 8 patients achieved an overall response (ORR) (ORR) based on the combined haematologic and imaging assessments of EMD. In contrast, among the 10 patients in the C group, 8 met the haematologic criteria for ORR, but only 6 demonstrated a radiographic response in EMD lesions. Progression-free survival (PFS) and overall survival (OS) were markedly improved in the T-C group. This cohort also exhibited higher peak levels of both CAR- T cells and IL-6. On day 28 post-infusion, the proportion of CD3⁺CD4⁺ T cells was significantly higher in the T-C group. While cytokine release syndrome (CRS) tended to be more severe in this group, the incidence and severity of the immune effector cell-associated neurotoxicity syndrome (ICANS) was comparable between the two groups. Haematologic recovery was delayed in the T-C group, and three of the eight patients developed poor graft function.</p> Conclusion <p>We retrospectively summarised the results of a 3-year follow-up and found that the combination of anti-BCMA CAR-T cell therapy and auto-HSCT was associated with improved PFS and OS in R/R MM patients with EMD. Moreover, CD4⁺ T-cell dynamics may be associated with the durable clinical response observed in the T-C group. Although the T-C group experienced higher-grade CRS and prolonged haematological toxicity, no treatment-related deaths due to treatment-related toxicities were observed. (Trial registration: ChiCTR2000033925).</p> Trial registration <p>Registration center: Tianjin First Central Hospital. Trial Registration Number: ChiCTR2000033925. Registration Date: June 17, 2020. The patient gave their written informed consent in accordance with the Declaration of Helsinki. The patients agreed to have their data used in our study.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Long-term follow-up results of anti-BCMA CAR-T cell therapy combined with autologous hematopoietic stem cell transplantation in relapsed/refractory multiple myeloma with extramedullary disease

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月25日

查看全文
  • Xin Li,
  • Can Liu,
  • Siyan Niu,
  • Ru Li,
  • Shuquan Gao,
  • Rui Cui,
  • Jia Wang,
  • Yao Qi,
  • Jingyi Li,
  • Qi Deng

摘要

Background

Relapsed/refractory multiple myeloma (R/R MM) with extramedullary disease (EMD) has a poor prognosis. Responses to current therapies, including autologous hematopoietic stem cell transplantation (auto-HSCT) and chimeric antigen receptor (CAR) T-cell therapy, remain unsatisfactory or show frequent early progression despite an initial response. In this study, we aimed to investigate the efficacy of a therapeutic approach combining CAR T-therapy with auto-HSCT.

Methods

Eighteen patients with R/R MM with EMD were enrolled in clinical trials evaluating anti-BCMA CAR-T therapy. Of these, eight patients were treated in combination with auto-ASCT in combination (T-C group), while the remaining ten underwent CAR T-cell therapy alone (C group). We retrospectively compared the clinical responses, CAR T-cell expansion kinetics, T-cell subset profiles, serum interleukin-6 (IL-6) levels, treatment-related toxicities, and long-term outcomes between the two cohorts.

Results

In the T-C group, all 8 patients achieved an overall response (ORR) (ORR) based on the combined haematologic and imaging assessments of EMD. In contrast, among the 10 patients in the C group, 8 met the haematologic criteria for ORR, but only 6 demonstrated a radiographic response in EMD lesions. Progression-free survival (PFS) and overall survival (OS) were markedly improved in the T-C group. This cohort also exhibited higher peak levels of both CAR- T cells and IL-6. On day 28 post-infusion, the proportion of CD3⁺CD4⁺ T cells was significantly higher in the T-C group. While cytokine release syndrome (CRS) tended to be more severe in this group, the incidence and severity of the immune effector cell-associated neurotoxicity syndrome (ICANS) was comparable between the two groups. Haematologic recovery was delayed in the T-C group, and three of the eight patients developed poor graft function.

Conclusion

We retrospectively summarised the results of a 3-year follow-up and found that the combination of anti-BCMA CAR-T cell therapy and auto-HSCT was associated with improved PFS and OS in R/R MM patients with EMD. Moreover, CD4⁺ T-cell dynamics may be associated with the durable clinical response observed in the T-C group. Although the T-C group experienced higher-grade CRS and prolonged haematological toxicity, no treatment-related deaths due to treatment-related toxicities were observed. (Trial registration: ChiCTR2000033925).

Trial registration

Registration center: Tianjin First Central Hospital. Trial Registration Number: ChiCTR2000033925. Registration Date: June 17, 2020. The patient gave their written informed consent in accordance with the Declaration of Helsinki. The patients agreed to have their data used in our study.